Daily DispatchDaily Dispatch

Outdated benefit laws and provincial disparities leave cancer patients navigating a broken funding maze

Navigating a tangled web of funding challenges for cancer in the private and public sectors

Public budget constraints and private medical aid hurdles keep cutting-edge therapies out of reach

Premium

Breakthrough cancer therapies are transforming survival rates globally, yet in South Africa, life-saving innovations remain largely out of reach. While public sector patients face severely constrained provincial budgets, private medical scheme members are confronted by outdated statutory frameworks, restrictive plan tiers, and devastating out-of-pocket co-payments.

From the complex procurement of essential drugs like trastuzumab to high-cost immunotherapies costing tens of thousands of rands per dose, systemic funding challenges continue to leave vulnerable patients navigating complex bureaucracy at their most critical hour.

A patient receiving cancer care at a public health facility in Gauteng.
A patient receiving cancer care at a public health facility in Gauteng. Picture: Rosetta Msimango/Spotlight

Breakthrough cancer treatments are bringing hope globally yet access in South Africa remains constrained by affordability.

Daily Dispatch

Subscriber access

There’s more to this story.

Sign in to continue reading. This article is reserved for subscribers. New here? Create an account to get started.